Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J KEATING

Showing results (751-760 of 1,115) with videos related to

Pageof 112
Sort By:
British Journal of Cancer|August 1, 1995
Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expressionP J Keating, F V Cromme, M Duggan-Keen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic LeukemiaPreetesh Jain, Michael J Keating, William G Wierda, et al.
Human Immunology|April 9, 2008
Novel sequence elements define ancestral haplotypes of the region encompassing complement factor HJoseph F Williamson, Craig A McLure, Paul N Baird, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1984
Prediction of complete remission in patients with refractory acute leukemia treated with AMSAE H Estey, M J Keating, T L Smith, et al.
Journal of the American College of Surgeons|February 3, 2023
Dispelling Dogma: American Association for Surgery of Trauma Prospective, Multicenter Trial of Index vs Delayed Fasciotomy after Extremity TraumaJane J Keating, Nathan Klingensmith, Alexis M Moren, et al.
Blood|May 16, 2014
Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinibDominik Wodarz, Naveen Garg, Natalia L Komarova, et al.
Cancer|August 15, 1988
Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemiaR S Walters, H M Kantarjian, M J Keating, et al.
Haematologica|July 7, 2018
Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathwaysLynne V Abruzzo, Carmen D Herling, George A Calin, et al.
Blood|January 10, 2009
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease courseConstantine S Tam, Lynne V Abruzzo, Katherine I Lin, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2013
Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndromeApostolia M Tsimberidou, William G Wierda, Sijin Wen, et al.
Pageof 112

Showing results (751-760 of 1,115) with videos related to

Sort By:
Pageof 112
British Journal of Cancer|August 1, 1995
Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expressionP J Keating, F V Cromme, M Duggan-Keen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic LeukemiaPreetesh Jain, Michael J Keating, William G Wierda, et al.
Human Immunology|April 9, 2008
Novel sequence elements define ancestral haplotypes of the region encompassing complement factor HJoseph F Williamson, Craig A McLure, Paul N Baird, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1984
Prediction of complete remission in patients with refractory acute leukemia treated with AMSAE H Estey, M J Keating, T L Smith, et al.
Journal of the American College of Surgeons|February 3, 2023
Dispelling Dogma: American Association for Surgery of Trauma Prospective, Multicenter Trial of Index vs Delayed Fasciotomy after Extremity TraumaJane J Keating, Nathan Klingensmith, Alexis M Moren, et al.
Blood|May 16, 2014
Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinibDominik Wodarz, Naveen Garg, Natalia L Komarova, et al.
Cancer|August 15, 1988
Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemiaR S Walters, H M Kantarjian, M J Keating, et al.
Haematologica|July 7, 2018
Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathwaysLynne V Abruzzo, Carmen D Herling, George A Calin, et al.
Blood|January 10, 2009
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease courseConstantine S Tam, Lynne V Abruzzo, Katherine I Lin, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2013
Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndromeApostolia M Tsimberidou, William G Wierda, Sijin Wen, et al.
Pageof 112